Randa Saeed, Stephen McSorley, Almudena Cascales, Donald C McMillan
{"title":"接受免疫治疗的非小细胞肺癌患者系统性炎症反应的预后/预测价值：一项系统综述和荟萃分析","authors":"Randa Saeed, Stephen McSorley, Almudena Cascales, Donald C McMillan","doi":"10.1186/s12885-025-13822-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The second most common malignancy after breast cancer is lung cancer (LC). Small cell lung cancer accounts for 15%, while non-small lung cancer (NSCLC) accounts for 85% of cases. Immunotherapy has improved treatment outcomes in NSCLC. However, the role of systemic inflammation-based prognostic scores in predicting response to treatment is not clear. The meta-analyses aims to evaluate the prognostic/ predictive value of inflammatory biomarkers, including NLR, ALI, PLR, CRP, and mGPS, and their potential associated with overall survival in NSCLC patients receiving immunotherapy as first-line or second-line treatment.</p><p><strong>Methods: </strong>A systematic review and meta-analysis was conducted following the Cochrane Handbook and PRISMA guidelines. Searches were performed in PubMed, Cochrane Library, and Web of Science for studies published until January 1, 2022, using specific keywords related to NSCLC, immunotherapy, inflammatory biomarkers and survival. Meta-analysis was performed using RevMan software, analyzing the hazard ratio (HRs) with a 95% confidence interval (CIs) primarily in relation to overall survival.</p><p><strong>Results: </strong>Six thirty three records were identified, and 17 articles were included in the meta-analysis. The pooled analysis of NLR, ALI, PLR, CRP, and mGPS was significantly associated with OS without significant heterogeneity (NLR: HR = 2.15; 95% CI 1.60 - 2.87; P-Value < 0.00001); (ALI: HR = 2.03; 95% CI 1.43 - 2.88; P-Value < 0.0001); (PLR: HR = 4.06; 95% CI 2.14 - 7.67; P-Value < 0.0001); (CRP: HR = 5.37; 95% CI 3.90 - 7.39; P-Value < 0.00001); and (mGPS: HR = 3.27; 95% CI 1.26 - 8.28; P-Value = 0.01), respectively.</p><p><strong>Conclusions: </strong>Systemic inflammatory biomarkers demonstrate independent prognostic/ predictive value in patients with advanced non-small cell lung cancer who receive immunotherapy as either the first-line or second-line therapy.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"994"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135607/pdf/","citationCount":"0","resultStr":"{\"title\":\"The prognostic/ predictive value of the systematic inflammatory response in patients receiving immunotherapy for non-small cell lung cancer: a systematic review and meta-analysis.\",\"authors\":\"Randa Saeed, Stephen McSorley, Almudena Cascales, Donald C McMillan\",\"doi\":\"10.1186/s12885-025-13822-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The second most common malignancy after breast cancer is lung cancer (LC). Small cell lung cancer accounts for 15%, while non-small lung cancer (NSCLC) accounts for 85% of cases. Immunotherapy has improved treatment outcomes in NSCLC. However, the role of systemic inflammation-based prognostic scores in predicting response to treatment is not clear. The meta-analyses aims to evaluate the prognostic/ predictive value of inflammatory biomarkers, including NLR, ALI, PLR, CRP, and mGPS, and their potential associated with overall survival in NSCLC patients receiving immunotherapy as first-line or second-line treatment.</p><p><strong>Methods: </strong>A systematic review and meta-analysis was conducted following the Cochrane Handbook and PRISMA guidelines. Searches were performed in PubMed, Cochrane Library, and Web of Science for studies published until January 1, 2022, using specific keywords related to NSCLC, immunotherapy, inflammatory biomarkers and survival. Meta-analysis was performed using RevMan software, analyzing the hazard ratio (HRs) with a 95% confidence interval (CIs) primarily in relation to overall survival.</p><p><strong>Results: </strong>Six thirty three records were identified, and 17 articles were included in the meta-analysis. The pooled analysis of NLR, ALI, PLR, CRP, and mGPS was significantly associated with OS without significant heterogeneity (NLR: HR = 2.15; 95% CI 1.60 - 2.87; P-Value < 0.00001); (ALI: HR = 2.03; 95% CI 1.43 - 2.88; P-Value < 0.0001); (PLR: HR = 4.06; 95% CI 2.14 - 7.67; P-Value < 0.0001); (CRP: HR = 5.37; 95% CI 3.90 - 7.39; P-Value < 0.00001); and (mGPS: HR = 3.27; 95% CI 1.26 - 8.28; P-Value = 0.01), respectively.</p><p><strong>Conclusions: </strong>Systemic inflammatory biomarkers demonstrate independent prognostic/ predictive value in patients with advanced non-small cell lung cancer who receive immunotherapy as either the first-line or second-line therapy.</p>\",\"PeriodicalId\":9131,\"journal\":{\"name\":\"BMC Cancer\",\"volume\":\"25 1\",\"pages\":\"994\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135607/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12885-025-13822-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-13822-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：肺癌（LC）是仅次于乳腺癌的第二常见的恶性肿瘤。小细胞肺癌占15%，非小细胞肺癌（NSCLC）占85%。免疫疗法改善了非小细胞肺癌的治疗效果。然而，基于全身性炎症的预后评分在预测治疗反应中的作用尚不清楚。该荟萃分析旨在评估炎症生物标志物的预后/预测价值，包括NLR、ALI、PLR、CRP和mGPS，以及它们与接受免疫治疗作为一线或二线治疗的非小细胞肺癌患者总生存率的潜在关联。方法：根据Cochrane手册和PRISMA指南进行系统回顾和荟萃分析。在PubMed、Cochrane Library和Web of Science中检索截至2022年1月1日发表的研究，使用与NSCLC、免疫治疗、炎症生物标志物和生存相关的特定关键词。使用RevMan软件进行meta分析，分析风险比（hr）， 95%置信区间（ci）主要与总生存率相关。结果：633条记录被识别，17篇文章被纳入meta分析。NLR、ALI、PLR、CRP和mGPS的合并分析与OS有显著相关性，且无显著异质性(NLR: HR = 2.15；95% ci 1.60 - 2.87；p值结论：系统性炎症生物标志物在接受一线或二线免疫治疗的晚期非小细胞肺癌患者中显示出独立的预后/预测价值。
The prognostic/ predictive value of the systematic inflammatory response in patients receiving immunotherapy for non-small cell lung cancer: a systematic review and meta-analysis.
Background: The second most common malignancy after breast cancer is lung cancer (LC). Small cell lung cancer accounts for 15%, while non-small lung cancer (NSCLC) accounts for 85% of cases. Immunotherapy has improved treatment outcomes in NSCLC. However, the role of systemic inflammation-based prognostic scores in predicting response to treatment is not clear. The meta-analyses aims to evaluate the prognostic/ predictive value of inflammatory biomarkers, including NLR, ALI, PLR, CRP, and mGPS, and their potential associated with overall survival in NSCLC patients receiving immunotherapy as first-line or second-line treatment.
Methods: A systematic review and meta-analysis was conducted following the Cochrane Handbook and PRISMA guidelines. Searches were performed in PubMed, Cochrane Library, and Web of Science for studies published until January 1, 2022, using specific keywords related to NSCLC, immunotherapy, inflammatory biomarkers and survival. Meta-analysis was performed using RevMan software, analyzing the hazard ratio (HRs) with a 95% confidence interval (CIs) primarily in relation to overall survival.
Results: Six thirty three records were identified, and 17 articles were included in the meta-analysis. The pooled analysis of NLR, ALI, PLR, CRP, and mGPS was significantly associated with OS without significant heterogeneity (NLR: HR = 2.15; 95% CI 1.60 - 2.87; P-Value < 0.00001); (ALI: HR = 2.03; 95% CI 1.43 - 2.88; P-Value < 0.0001); (PLR: HR = 4.06; 95% CI 2.14 - 7.67; P-Value < 0.0001); (CRP: HR = 5.37; 95% CI 3.90 - 7.39; P-Value < 0.00001); and (mGPS: HR = 3.27; 95% CI 1.26 - 8.28; P-Value = 0.01), respectively.
Conclusions: Systemic inflammatory biomarkers demonstrate independent prognostic/ predictive value in patients with advanced non-small cell lung cancer who receive immunotherapy as either the first-line or second-line therapy.
期刊介绍：
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
